Lung Cancer

Studies show that the social stigma can actually affect a patient’s level of care and lead to worse health outcomes.

Tumor mutation burden may be an independent predictor of developing depression in patients with lung cancer, according to Dr. Daniel McFarland.

The growing use of telecommunication and technology to provide health care – or telemedicine – offers many advantages, but also comes with challenges, says one expert.

Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.

From cancer-sniffing dogs to music therapy for pain, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration approved Keytruda for the treatment of patients with metastatic small cell lung cancer.

Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.

In this week’s episode of the “CURE® Talks Cancer” podcast, we spoke with a caregiver who found hope in the darkness after losing her son to lung cancer at just 29 years old.

I have stage 4 lung cancer and told I had 12-18 months to live. Little did I know they sent a biopsy off for genome testing which has given me six years so far. My life is incredibly imperfect, but I love every single minute of it.

Jennifer King, from the GO2 Foundation for Lung Cancer, discussed what patients can do to help address the stigma associated with lung cancer.

Genomic testing has transformed the therapeutic landscape of lung cancer in recent years, but there is still room for improvement, says one expert.

Here are the top 5 CURE stories for May 2019.

Precision medicine has prolonged life for many with lung cancer, giving them opportunities to support those who are newly diagnosed.

"Alvin David, B.S.N., RN-BC, wrote this exemplar as part of his promotion to clinical nurse 3. I will let his words do the talking, as they reveal his true essence as a nurse, colleague, preceptor, friend, father, husband and extraordinary healer," wrote Margie McDonald, M.S.N., RN, CBCN of Memorial Sloan Kettering Monmouth.

We've got a sneak peek at what’s inside CURE®'s lung cancer special issue.

With nearly 30 years of experience in thoracic oncology, one expert discusses what lies ahead for patients with small cell lung cancer.

LUNGevity’s annual summit helps people with lung cancer live better and stay informed.

Thousands of new patients are now able to enroll in Lung Cancer Master Cancer Protocol, a National Cancer Institute trial. Criteria have been expanded to allow patients with all types of non-small cell lung cancer.

Two husbands embrace changing and challenging roles at home when they learn of their spouses’ cancer diagnoses.

A pre-surgical shape-up could improve recovery for patients with lung cancer. Although the findings are still emerging, some researchers think that prehab may be a key player that will improve patient outcomes in this changing environment.

Testing for genomic mutations in lung cancer helps pinpoint targeted therapies.

Researchers examined the prevalence of chronic opioid use among survivors of breast, colorectal and lung cancer.

The Food and Drug Administration expanded the approval for the first and only companion diagnostic to identify patients with non-small cell lung cancer who would benefit from Keytruda treatment.

Researchers found significant gender and role differences regarding cardiovascular disease incidence and its related health behaviors among cancer survivors and their spouses.

The Food and Drug Administration approved Keytruda (pembrolizumab) for the first-line treatment of patients with a lower PD-L1 cutoff in non-small cell lung cancer.

Survey results show that when one or more chronic condition was present physicians discussed trial participation with less than half of patients.

Previously treated patients with advanced small cell lung cancer (SCLC) benefitted from immunotherapy.

Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."

Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."

Patients with previously treated, advanced NSCLC who received Opdivo therapy experienced a survival benefit over many years, according to a pooled analysis of four studies.